$TEM

West Nadja sold $162K of TEM

West Nadja sold 3,000 shares of Tempus AI, Inc. (TEM) at $53.90 ($0.16M total) on 2026-08-14 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · West Nadja
Published Aug 18, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 8:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TEM
Neutral
high confidence
Mentioned
$TEM
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEMNeutralLow
01

Why it matters

The newest fact is the specific open-market sale details: 3,000 shares at $53.90 on 2026-08-14, with holdings after the sale of 34,981 shares, executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may log the insider sale for sentiment monitoring, but the 10b5-1 structure makes it less actionable as a standalone catalyst.

03

What to watch

The article does not provide context on total holdings, prior sale frequency, or whether the sale was tax-related, limiting inference from the transaction size.

Relevance 3/10Novelty 3/10Timing: Filed 2026-08-18, disclosing an insider sale executed 2026-08-14.

Background

The article is an SEC Form 4 insider transaction disclosure for Tempus AI, Inc. (TEM).

Company-level read

Ticker impact

$TEMNeutralHigh confidence
Context

Tempus AI director West Nadja sold 3,000 shares in an open-market transaction at $53.90 on 2026-08-14 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this Form 4 sale; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is an SEC Form 4 insider transaction, but it specifies a 10b5-1 pre-arranged plan, which typically reduces interpretive value versus discretionary selling.

Market effects

Minimal, as the disclosure is company-specific and does not indicate sector-wide regulatory or demand changes.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still coincide with internal caution, so traders may watch for follow-on sales or other insider activity.

Key entities

  • Tempus AI, Inc.

    Company whose director insider sale is disclosed via SEC Form 4.

  • West Nadja

    Director who sold 3,000 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TEMMed

What Happens To Tempus AI Stock If Its Cash Burn Continues?

Tempus AI (TEM) expects positive free cash flow by year-end but had a $273M cash burn over the past year. With $816M in cash, the company's reserves could last about three years at current burn rates. Revenue grew 20% and 36% in diagnostics and data businesses, respectively. Management raised 2026 revenue guidance to $1.595B-$1.605B and issued $460M in convertible notes. The company plans to acquire Personalis, potentially using debt to fund the deal.

$BMYMed

Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological Conditions

Pathos AI has partnered with Bristol Myers Squibb (BMY) and Tempus (TEM) to advance AI-driven drug development for Alzheimer’s and other neurological conditions. Tempus will create a dataset from hundreds of thousands of patients, which Pathos will license for $55 million over five years. BMY leads Pathos's Series E financing and gains access to Pathos's AI platform, Pathos Foundry, for its R&D portfolio, with exclusive rights in neuroscience for three years.

$BMYMed

Tempus Sets $55 Million Ceiling for Pathos Neurology Data Contract

Tempus AI signed a five-year neurology data deal with Pathos AI, potentially worth $55 million. Tempus will deliver up to 500,000 records, with Pathos paying $100 per record. Bristol Myers Squibb gains nonexclusive Foundry access and three-year exclusive rights for neuroscience development. Tempus also has a $137.5 million oncology deal with BMS, totaling $192.5 million if both deals reach full value.

$TEMMed

Tempus AI Gains 6% as Bristol Myers Squibb Licenses Oncology Data

Tempus AI shares rose 6% after Bristol Myers Squibb agreed to a multi-year deal to license its oncology data through 2031. Tempus's data and AI platform will support BMS's drug discovery and development. Data licensing is Tempus's most profitable segment, with 36% revenue growth in Q2. The financial terms of the deal were not disclosed.